Industry News

Quality Systems, Inc. announced today results for its fiscal 2017 first quarter ended June 30, 2016.. “In the first quarter, we saw a number of positive developments as we continued to execute on our strategic plan and have made great progress reinvigorating the culture of our organization,” commented Rusty Frantz, president and chief executive officer of Quality Systems, Inc.“ In addition, we remain focused on our solutions integration and product roadmap..."/>
Quality Systems, Inc. Reports Fiscal 2017 First Quarter Results
BD Names R. Andrew Eckert To Board Of Directors
Vocera Communications, Inc., a leading healthcare communications company, today reported total revenue of $31.2 million, an increase of 22% compared to revenue of $25.4 million in the second quarter of 2015.. “The second quarter of 2016 was another strong quarter for our business. The market for our products is expanding, and our platform offering is resonating with customers who are looking for solutions to solve communication and collaboration..."/>
Vocera Announces Second Quarter Revenue of $31.2 million and Raises FY’16 Guidance
ATI Airtest Technologies Inc.. Resumption: July 29, 2016, 08:00 AM."/>
IIROC Trading Resumption - AAT; APH
Omnicell, Inc. today announced that Rochester Regional Health, a five-hospital health system in western New York, has selected the Company's medication automation solutions for its hospital floors and operating rooms to promote the highest level of patient care. Formed in 2014, Rochester Regional is currently installing Omnicell ® automated medication dispensing systems in two of its five hospitals that collectively serve..."/>
Omnicell Selected to Provide Interoperable Medication Automation Solutions to Support Patient Safety at Rochester Regional Health
Agile Therapeutics, Inc., today announced the appointment of Seth H. Z. Fischer to the Company's Board of Directors, effective July 28, 2016. Fischer will serve on Agile’ s Compensation and Nominating& Corporate Governance Committees.. “We are very pleased to welcome Seth to our board of directors,” stated Al Altomari, President and Chief Executive Officer of Agile.“ Seth’ s significant commercial background, including expertise in leading and developing..."/>
Agile Therapeutics Appoints Seth H. Z. Fischer to its Board of Directors
Mettler-Toledo International Inc. today announced second quarter results for 2016. Provided below are the highlights:. Sales in local currency increased 6% in the quarter compared with the prior year."/>
Mettler-Toledo International Inc. Reports Second Quarter 2016 Results
Quotient Limited, a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares.. Jefferies LLC is acting as sole bookrunner for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be..."/>
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
Vocera Communications, Inc., the leading healthcare communications company, today announced that Alexa King, executive vice president and general counsel at FireEye, joined Vocera’ s Board of Directors effective July 27, 2016.. Since 2012, King has led the legal team at FireEye, the leading security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber-attacks."/>
FireEye EVP and General Counsel Alexa King Joins Vocera Board of Directors
AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a corporate update and reported financial results for the three and six months ended June 30, 2016.. ARX-04 Clinical and Commercial Update:. AcelRx completed enrollment in two Phase 3 studies: SAP302, which treated a total of 76 patients who..."/>
AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results
Pfizer Inc. announced today top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis Sustain, the third Phase 3 study of XELJANZ ® being investigated in patients with moderately to severely active ulcerative colitis. OCTAVE Sustain is a 52 week study that evaluated oral tofacitinib 5 mg and 10 mg twice daily as a maintenance treatment in adult patients with moderately to severely active UC who previously completed and achieved clinical..."/>
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis
Dicerna Pharmaceuticals, Inc., a leading developer of investigational RNA interference therapeutics, today announced that the Company will release its second quarter 2016 financial results after market close on Thursday, August 4, 2016.. Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be..."/>
Dicerna to Report Second Quarter 2016 Financial Results and Host Conference Call on August 4, 2016
OvaScience SM, a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. EDT on Thursday, August 4, 2016 to discuss second quarter 2016 financial results and provide a general corporate update. The live call can be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the..."/>
OvaScience to Host Second Quarter 2016 Financial Results Conference Call
Alliance HealthCare Services announced today that it will host a conference call and webcast on Thursday, August 4, 2016, at 5 p.m. Eastern Time, to discuss the Company’ s second quarter 2016 financial results, which are scheduled to be released after the market closes on Thursday, August 4, 2016. Tom Tomlinson, Chief Executive Officer and President, is scheduled to host the call."/>
Alliance HealthCare Services Schedules Conference Call for Second Quarter 2016 Financial Results
Innoviva, Inc. today reported financial results for the second quarter ended June 30, 2016."/>
Innoviva Reports Second Quarter 2016 Financial Results
Tandem Diabetes Care ®, Inc., a medical device company and manufacturer of the t: slim ®, t: slim G4™ and t: flex ® Insulin Pumps, today reported its financial results for the quarter ended June 30, 2016 and updated its financial guidance for the year ending December 31, 2016. The Company also announced the development of a next generation pump platform, the t: slim X2™ Insulin Pump, which the Company is planning to launch in the fourth quarter of 2016. With today’ s announcement, the..."/>
Tandem Diabetes Care Reports Second Quarter 2016 Financial Results, Updates 2016 Guidance and Announces New t:slim X2™ Insulin Pump and Associated Technology Upgrade Program
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration..."/>
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
Neos Therapeutics, Inc., a pharmaceutical company focused on developing and commercializing innovative extended-release products for the treatment of attention-deficit/hyperactivity disorder, today announced the successful completion of a bioequivalence bridging study for its late stage product candidate, Cotempla XR-ODT.. Cotempla XR-ODT met all of the primary and secondary endpoints, including partial AUCs, for..."/>
Neos Therapeutics Announces Successful Completion of Bioequivalence Bridging Study for Cotempla XR-ODT™ (Methylphenidate Extended-Release Orally Disintegrating Tablet)
ResMed Inc. today announced results for its quarter ended June 30, 2016. Revenue for the quarter was $518.6 million, a 14 percent increase compared to the same period of the prior year, or a 15 percent increase on a constant currency basis. Excluding the contribution from the Brightree acquisition, revenue for the quarter was $489.7 million, an 8 percent increase."/>
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016
Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the first quarter of fiscal year..."/>
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration..."/>
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
IRIDEX Corporation today announced that it will release its second quarter 2016 financial results after the market closes on Thursday, August 4, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, August 4, 2016 to discuss the results of the quarter and other business developments. Interested parties may access the live conference..."/>
IRIDEX Announces Second Quarter 2016 Conference Call and Release Date
Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone for growth hormone deficiency, today announced financial results for the second quarter ended June 30, 2016 and provided an update on its clinical development programs.. “We are approaching an important milestone in the somavaratan development program with the completion of..."/>
Versartis Reports Second Quarter 2016 Financial Results
HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016 in Boston.. HTG management is scheduled to present at 8:00 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the“ Investors” section of HTG’ s website at: http://www.htgmolecular.com."/>
HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.. Revenue for the second quarter of 2016 was $12.5 million, an increase of 64% over the prior..."/>
GenMark Diagnostics Reports Q2 Financial Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials963 Articles
Information Technology907 Articles
Consumer Discretionary768 Articles
Industrials602 Articles
Health Care597 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.